Fosclevudine alafenamide

DB19113InvestigationalSmall molecule

Fosclevudine alafenamide is under investigation in clinical trial NCT05238844 (A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis...

Mechanism: Pharmacologically active on Reverse transcriptase
Curator reviewed
Formula / weight: C₂₂H₂₉FN₃O₉P · 529.458 g/mol (avg)
Also known as: L-alanine, n-((s)-hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-(2-deoxy-2-fluoro-.beta.-l-arabinofuranosyl)-5-methyl-2,4(1h,3h)-pyrimidinedione
Code names: AT-2173 · ATI-2173

Resolves to

Compound

UNII77AP23J0GHCAS1951476-79-1ChEMBLCHEMBL5095214

Structure

InChIKeyFTMNZJASLMPPNW-MHFVGYLCSA-NSMILESCC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1O[C@@H]([C@H](F)[C@H]1O)N1C=C(C)C(=O)NC1=O)OC1=CC=CC=C1

Targets

Q3MS49rt

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Fosclevudine alafenamide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account